For patients with advanced cervical cancer, cisplatin plus pemetrexed may be effective
the ONA take:
According to a new study published in the Journal of Clinical Oncology, cisplatin plus pemetrexed improved response rates and survival rates of patients with advanced cervical cancer. In the phase 2 study, researchers assigned patients with advanced, persistent, or recurrent cervical cancer to received either cisplatin in combination with pemetrexed or paclitaxel.
Researchers found that patients with no prior history of chemotherapy that received cisplatin plus pemetrexed had a 31% response rate for a duration of up to 7 months and an overall survival of 12 months. Patients that received cisplatin plus paclitaxel had a 29% response rate for a duration of up to 6 months and an overall survival of 13 months.
Furthermore, the pemetrexed combination was observed to be less toxic compared with the paclitaxel combination. Researchers also observed increased survival rates when adding bevacizumab to the paclitaxel combination, so researchers suggest possibly adding bevacizumab to the pemetrexed combination.
According to the Centers for Disease Control and Prevention (CDC), cervical cancer used to be the leading cause of cancer-related death in women in the United States, but regular Pap screenings have led to early cancer detection and decreased mortality.
Cisplatin plus pemetrexed improved response rates in patients with advanced cervical cancer.
Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.
The cancer-fighting cocktail, which combines the chemotherapy drug cisplatin with pemetrexed - an agent that stops cancer cells from dividing - showed promising results for advanced, persistent, or recurrent cervical cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|